Aripiprazole Tablet
Product Images NDC 43547-889

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 43547-889). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare U.s., Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image1 (Structure)

Chemical structure of aripiprazole, the active ingredient in ARIPIPRAZOLE oral tablets by Solco Healthcare U.S., LLC. The diagram shows the molecular framework including chlorine-substituted aromatic rings, piperazine ring, and quinolinone moiety.*

FDA Label Image

Pl Figure 1 (Figure1.png)

A pharmacokinetic chart illustrating the fold change and 90% confidence intervals of aripiprazole levels in presence of various interacting drugs. The x-axis shows fold change relative to reference without interacting drug. The y-axis lists different drug categories and specific drugs such as ketoconazole (CYP3A4 inhibitor), quinidine (CYP2D6 inhibitor), carbamazepine (CYP3A4 inducer), famotidine (gastric acid blocker), valproate, and lorazepam, displaying their effects on aripiprazole AUC and Cmax values.*

FDA Label Image

Figure2 (2f5cad93 Figure 02)

A pharmacokinetic chart showing the effect of other drugs on Aripiprazole, specifically comparing dehydro-aripiprazole fold change and 90% confidence intervals for area under the curve (AUC) and maximum concentration (Cmax). The chart lists drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, and lorazepam, showing their relative impact on these PK parameters compared to a reference without interacting drugs.*

FDA Label Image

Figure3 (2f5cad93 Figure 03)

A forest plot chart titled 'Effect of Aripiprazole on Other Drugs' displaying fold change and 90% confidence intervals for various drugs metabolized by enzymes like CYP2D6, CYP2C9, CYP2C19, UGT1A4, and others. The x-axis represents change relative to reference (without interacting drug) ranging from 0.0 to 3.0. The y-axis lists drugs such as dextromethorphan, warfarin isomers, omeprazole, lamotrigine, valproate, lorazepam, venlafaxine, and O-desmethylvenlafaxine, with measurements of pharmacokinetic parameters including AUC and Cmax.*

FDA Label Image

Figure4 (2f5cad93 Figure 04)

A pharmacokinetic chart showing aripiprazole fold change and 90% confidence intervals for various special populations, comparing parameters AUC and Cmax. The chart compares poor versus extensive CYP2D6 metabolizers, gender differences, age groups (18-64 vs. >65 years), degrees of hepatic impairment, and severe renal impairment, illustrating relative changes to a reference.*

FDA Label Image

Figure 5 (2f5cad93 Figure 05)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the fold change in AUC and Cmax relative to reference across various patient factors including CYP2D6 metabolizer status, gender, age, hepatic impairment, and renal impairment. Data points with confidence intervals illustrate fold changes for poor vs. extensive metabolizers, female vs. male, age groups 18-64 vs. over 65, and levels of hepatic and renal impairment.*

FDA Label Image

6 (2f5cad93 Figure 06)

A Kaplan-Meier survival curve showing the proportion of subjects with relapse over time in days from randomization, comparing aripiprazole to placebo. The graph includes a table below indicating the number of subjects at risk at various time points for both treatment groups.*

FDA Label Image

7 (2f5cad93 Figure 07)

A line graph comparing the proportion of subjects with relapse over days from randomization between aripiprazole and placebo groups. The x-axis indicates days from randomization ranging from 0 to 182, and the y-axis shows the proportion with relapse from 0.0 to 1.0. Two curves, one solid for aripiprazole and one dashed for placebo, display relapse progression over time. The number of subjects at risk is presented for various days below the x-axis.*

FDA Label Image

8 (2f5cad93 Figure 08)

A line graph comparing the proportion of subjects with relapse over 364 days from randomization between aripiprazole and placebo groups. The graph shows lower relapse rates in the aripiprazole group compared to placebo, with numbers of subjects at risk displayed below the x-axis for both groups at various time points.*

FDA Label Image

Figure9 (Image 01)

Line graph showing change in YGTSS total tic score from baseline over 8 weeks of treatment. It compares three groups: Aripiprazole Low, Aripiprazole High, and Placebo. The y-axis measures least-squares mean change in YGTSS total tic score, with the score decreasing over time. Aripiprazole High shows the greatest reduction, followed by Aripiprazole Low, then Placebo with the least change.*

FDA Label Image

Pl Labels 2 mg (2mg)

FDA Label Image

Pl Label 5mg (5mg)

FDA Label Image

Pl Label 10mg (10mg)

FDA Label Image

Pl Labels 15mg (15mg)

FDA Label Image

Pl Labels 20mg (20mg)

FDA Label Image

Pl Labels 30mg (30mg)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.